The new patented compounds are based on a potent reversible noncovalent mechanism of action, which is useful for treating MAGL-mediated diseases, such as neuroinflammation/degeneration, pain, multiple sclerosis/amyotrophic lateral sclerosis, Alzheimer's disease, and Parkinson's disease.

Settore:

Life sciences

Research Institution:

Università di Pisa

Publication number:

EP3889132B1

Technologies, Systems, Applications:

New drugs development

Technological Priority:

Biomedical, pharmaceutical, pharmacological technologies,
Biotechnologies for health
Pubblicato il:
Torna in cima alla pagina